EconPapers    
Economics at your fingertips  
 

Pharmaceutical promotion and GP prescription behaviour

Frank Windmeijer (), Eric de Laat, Rudy Douven and Esther Mot
Additional contact information
Eric de Laat: CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, The Netherlands, Postal: CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, The Netherlands
Rudy Douven: CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, The Netherlands, Postal: CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, The Netherlands
Esther Mot: CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, The Netherlands, Postal: CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, The Netherlands

Health Economics, 2006, vol. 15, issue 1, 5-18

Abstract: The aim of this paper is to empirically analyse the responses by general practitioners to promotional activities for ethical drugs by pharmaceutical companies. Promotion can be beneficial as a means of providing information, but it can also be harmful in the sense that it lowers price sensitivity of doctors and it merely is a means of maintaining market share, even when cheaper, therapeutically equivalent drugs are available. A model is estimated that includes interactions of promotion expenditures and prices and that explicitly exploits the panel structure of the data, allowing for drug specific effects and dynamic adjustments, or habit persistence. The data used are aggregate monthly GP prescriptions per drug together with monthly outlays on drug promotion for the period 1994-1999 for 11 therapeutic markets, covering more than half of the total prescription drug market in the Netherlands. Identification of price effects is aided by the introduction of the Pharmaceutical Prices Act, which established that Dutch drugs prices became a weighted average of the prices in surrounding countries after June 1996. We conclude that GP drug price sensitivity is small, but adversely affected by promotion. Copyright © 2005 John Wiley & Sons, Ltd.

Date: 2006
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (11) Track citations by RSS feed

Downloads: (external link)
http://hdl.handle.net/10.1002/hec.1007 Link to full text; subscription required (text/html)

Related works:
Working Paper: Pharmaceutical promotion and GP prescription behaviour (2004) Downloads
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:15:y:2006:i:1:p:5-18

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().

 
Page updated 2019-08-21
Handle: RePEc:wly:hlthec:v:15:y:2006:i:1:p:5-18